Actively Recruiting
Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2023-10-11
84
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To develop postoperative stratification treatment for patients who have received induction chemotherapy and immunotherapy in locally advanced head and neck cancers. Risk stratification is based on clinical characteristics and pathological responses. In order to achieve no inferior survival rate and a lower treatment-related toxicity rate than the standard treatment.
CONDITIONS
Official Title
Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Histopathologically confirmed squamous cell carcinoma of the head and neck
- Locally advanced cancer diagnosed as T3-4 or N+ stage according to AJCC 8th edition
- ECOG performance score of 0 or 1
- No distant metastasis present
- Received induction chemotherapy plus immunotherapy followed by surgery
- Expected survival of at least 6 months
- No contraindications to chemotherapy, immunotherapy, and radiotherapy
You will not qualify if you...
- History of past malignancies except stage I non-melanoma skin cancer or cervical carcinoma in situ
- Received systemic anti-tumor therapy for target lesions before induction chemotherapy and immunotherapy
- Previous radiation therapy to the head and neck region
- Use of corticosteroids over 10 mg/day prednisone or other immunosuppressive agents within 1 month before enrollment (except certain permitted uses)
- Presence of pleural, pericardial effusion, or ascites requiring drainage or recent drainage within 2 weeks
- Severe comorbid conditions including myocardial infarction, arrhythmia, cerebral vascular disease, ulcer disease, mental illness, or uncontrolled diabetes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC
Beijin, Beijing Municipality, China, 51000
Actively Recruiting
Research Team
Y
Yi Xu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here